Real‐life effectiveness of first‐line anticancer treatments in stage IIIB/IV NSCLC patients: Data from the Czech TULUNG Registry

Real‐life effectiveness of first‐line anticancer treatments in stage IIIB/IV NSCLC patients: Data from the Czech TULUNG Registry

Background Data regarding real‐life effectiveness of any treatment may improve clinical decision‐making. The aim of this study was to evaluate real‐life effectiveness of tyrosin‐kinase inhibitors, bevacizumab and pemetrexed as first‐line treatments in patients with advanced/metastatic non‐small cell...

Full description

Bibliographic Details
Main Authors: Kristian Brat, Monika Bratova, Jana Skrickova, Magda Barinova, Karolina Hurdalkova, Milos Pesek, Libor Havel, Leona Koubkova, Michal Hrnciarik, Jana Krejci, Ondrej Fischer, Milada Zemanova, Helena Coupkova, Martin Svaton
Format: Article
Language:English
Published: Wiley 2020-11-01
Series:Thoracic Cancer
Subjects:
Anticancer treatment
non‐small cell lung cancer
progression‐free survival
real‐life effectiveness
tyrosinkinase inhibitors
Online Access:https://doi.org/10.1111/1759-7714.13679

Internet

https://doi.org/10.1111/1759-7714.13679

Similar Items